The first of the National Institute of Allergy and Infectious Diseases’ (NIAID) Covid-19 research priorities is to improve understanding of the disease and the novel coronavirus that causes it, SARS-CoV-2.
This helps with understanding the transmission of the disease, including determining whether it is likely to be seasonally circulating, as well as why Covid-19 so dramatically affects some individuals, while others remain asymptomatic.
But better knowledge about the virus and the disease can also support the identification of new drug targets or which existing drugs could help tackle this viral disease.
Drugs are essential to stopping more suffering at the hands of Covid-19; at the time of writing, more than 206,000 people have